Affiliation:
1. Yasuj University of Medical Sciences
2. Shiraz University of Medical Sciences School of Pharmacy
3. Tabriz University of Medical Sciences Faculty of Pharmacy
4. Cape Breton University Canadian International College: Canadian International College
Abstract
Abstract
Background
Successful gene therapy relies on carriers to transfer genetic materials with high efficiency and low toxicity in a targeted manner. To improve targeted cell binding and uptake, we developed and synthesized a new gene delivery vector based on graphene oxide (GO) modified by branched polyethyleneimine (BPEI) and folic acid (FA).
Methods and Results
The GO-PEI-FA nanocarriers exhibit less toxicity as compared to the unmodified PEI, as well as having potential efficacy in compressing and protecting pDNA. Interestingly, by increasing the polymer content in the polyplex formulation, the plasmid transfer ability increased. Graphene oxide substitution of PEI at N/P:10 on HepG2 cell line, improved hIL-12 expression by up to around eight folds relative to the simple PEI, which is 2-fold higher than Go-PEI-FA on Hek293 at the same N/P ratio.
Conclusions
Hence, the GO-PEI-FA described in this study might introduce as a targeting nanocarrier for delivery of hIL-12 plasmid into the cells overexpressing folic acid receptors, such as hepatocellular carcinoma.
Publisher
Research Square Platform LLC
Reference48 articles.
1. SINGAL AG, NAGAR SP, HITCHENS A, DAVIS KL, IYER S (2021) Real-World Effectiveness of Lenvatinib in Hepatocellular Carcinoma Patients with Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology
2. Interleukin-12 plasmid DNA delivery by N-[(2-Hydroxy-3-trimethylammonium) propyl] chitosan-based nanoparticles;DEHSHAHRI A;Polymers,2022
3. Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma;LAI I;J Immunother Cancer,2018
4. Cytokine-based cancer immunotherapy: Challenges and opportunities for IL-10;RALLIS KS;Anticancer Res,2021
5. Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System®(RTS®) gene switch as gene therapy for the treatment of glioma;BARRETT JA;Cancer Gene Ther,2018